Home • Search • Translate
From Wikipedia, the free encyclopedia
Dinaciclib
Clinical data
Other namesSCH-727965
Legal status
Legal status
  • Investigational
Identifiers
  • (S)-3-(((3-Ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)pyridine 1-oxide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard ( EPA)
ECHA InfoCard 100.246.885 Edit this at Wikidata
Chemical and physical data
FormulaC21H28N6O2
Molar mass396.495 g·mol−1
3D model ( JSmol)
  • CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO
  • InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1
  • Key:PIMQWRZWLQKKBJ-SFHVURJKSA-N

Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs). [1] It is being evaluated in clinical trials for various cancer indications. [2]

Dinaciclib is being developed by Merck & Co. It was granted orphan drug status by the FDA in 2011. [3]

Mechanisms of action

Anti-tumoral action

  • In melanoma
    • The anti-melanoma activity of dinaciclib is dependent on p53 signaling. [6]
  • In chronic lymphocytic leukemia (CLL)
    • Dinaciclib promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. [7]
  • In pancreatic cancer
  • In osteosarcoma
    • Dinacliclib induces the apoptosis of osteosarcoma cells. [9]
    • Apoptosis of osteosarcoma cultures can be induced by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. [10]


Role in developing neurons

In primary cultured neurons, dinaciclib regulates neurogenesis, where it reduces expression of upper layer marker Satb2, and induces CTIP2, expressed in neurons of deeper layers. [11]

Clinical trials

  • Phase II
    • Advanced breast cancer [12]
    • Non-small cell lung cancer (NSCLC) [13]
    • Multiple myeloma [14]
    • Advanced melanoma [15]
  • Phase III
    • A comparison of dinaciclib and ofatumumab for treatment of CLL [16]

References

  1. ^ Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. (August 2010). "Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor". Molecular Cancer Therapeutics. 9 (8): 2344–2353. doi: 10.1158/1535-7163.MCT-10-0324. PMID  20663931.
  2. ^ Bose P, Simmons GL, Grant S (June 2013). "Cyclin-dependent kinase inhibitor therapy for hematologic malignancies". Expert Opinion on Investigational Drugs. 22 (6): 723–738. doi: 10.1517/13543784.2013.789859. PMC  4039040. PMID  23647051.
  3. ^ "Dinaciclib". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 January 2017.
  4. ^ Martin MP, Olesen SH, Georg GI, Schönbrunn E (November 2013). "Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains". ACS Chemical Biology. 8 (11): 2360–2365. doi: 10.1021/cb4003283. PMC  3846258. PMID  24007471.
  5. ^ Nguyen TK, Grant S (March 2014). "Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism". Molecular Cancer Therapeutics. 13 (3): 662–674. doi: 10.1158/1535-7163.MCT-13-0714. PMC  3970263. PMID  24362465.
  6. ^ Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, et al. (2013). "The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling". PLOS ONE. 8 (3): e59588. Bibcode: 2013PLoSO...859588D. doi: 10.1371/journal.pone.0059588. PMC  3601112. PMID  23527225.
  7. ^ Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, et al. (December 2012). "The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells". Leukemia. 26 (12): 2554–2557. doi: 10.1038/leu.2012.144. PMC  3645353. PMID  22791353.
  8. ^ Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, et al. (October 2011). "Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models". Cancer Biology & Therapy. 12 (7): 598–609. doi: 10.4161/cbt.12.7.16475. PMC  3218385. PMID  21768779.
  9. ^ Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J, et al. (June 2011). "The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells". Molecular Cancer Therapeutics. 10 (6): 1018–1027. doi: 10.1158/1535-7163.MCT-11-0167. PMC  4727401. PMID  21490307.
  10. ^ Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ (March 2013). "Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor". Cell Death & Disease. 4 (3): e566. doi: 10.1038/cddis.2013.101. PMC  3613821. PMID  23538447.
  11. ^ Ambrozkiewicz MC, Bessa P, Salazar-Lázaro A, Salina V, Tarabykin V (November 2017). "Satb2Cre/+ mouse as a tool to investigate cell fate determination in the developing neocortex". Journal of Neuroscience Methods. 291: 113–121. doi: 10.1016/j.jneumeth.2017.07.023. PMID  28782628. S2CID  140208929.
  12. ^ Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, et al. (June 2014). "Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer". Clinical Breast Cancer. 14 (3): 169–176. doi: 10.1016/j.clbc.2013.10.016. PMID  24393852.
  13. ^ Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, et al. (February 2014). "Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer". Lung Cancer. 83 (2): 219–223. doi: 10.1016/j.lungcan.2013.11.020. PMID  24388167.
  14. ^ Clinical trial number NCT01096342 for "Phase II Trial of CDK Inhibitor Sch 727965 in Multiple Myeloma" at ClinicalTrials.gov
  15. ^ Clinical trial number Phase II Trial of Sch 727965 (NSC 747135) in Patients with Stage IV Melanoma NCT00937937A Phase II Trial of Sch 727965 (NSC 747135) in Patients with Stage IV Melanoma at ClinicalTrials.gov
  16. ^ Clinical trial number NCT01580228 for "A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia" at ClinicalTrials.gov

External links 









Retrieved from "
https://en.wikipedia.org/?title=Dinaciclib&oldid=1188855566"

					
				

			
			
		

		

					

							

		


						
From Wikipedia, the free encyclopedia

					

					

					
					
					


Dinaciclib


Clinical data
Other namesSCH-727965
Legal status

Legal status


  • Investigational


Identifiers



  • (S)-3-(((3-Ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)pyridine 1-oxide



CAS Number

PubChem 
CID

IUPHAR/BPS

ChemSpider

UNII

KEGG

ChEMBL

PDB ligand

CompTox Dashboard (
EPA)

ECHA InfoCard
100.246.885 
Edit this at Wikidata
Chemical and physical data

FormulaC21H28N6O2

Molar mass396.495 g·mol−1
3D model (
JSmol)



  • CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO





  • InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1
  • Key:PIMQWRZWLQKKBJ-SFHVURJKSA-N




Dinaciclib (SCH-727965) is an experimental drug that inhibits 
cyclin-dependent kinases (CDKs).
[1] It is being evaluated in clinical trials for various cancer indications.
[2]

Dinaciclib is being developed by 
Merck & Co. It was granted 
orphan drug status by the FDA in 2011.
[3]




Mechanisms of action




Anti-tumoral action



  • In 
melanoma

    • The anti-melanoma activity of dinaciclib is dependent on p53 signaling.
[6]
    • 

  • In 
chronic lymphocytic leukemia (CLL)

    • Dinaciclib promotes 
apoptosis and abrogates microenvironmental 
cytokine protection in chronic lymphocytic leukemia cells.
[7]
    • 

  • In 
pancreatic cancer

    • 

  • In osteosarcoma

    • Dinacliclib induces the apoptosis of osteosarcoma cells.
[9]
      • 

    • Apoptosis of osteosarcoma cultures can be induced by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.
[10]







Role in developing neurons



In primary cultured neurons, dinaciclib regulates neurogenesis, where it reduces expression of upper layer marker 
Satb2, and induces 
CTIP2, expressed in neurons of deeper layers.
[11] 





Clinical trials



  • Phase II

    • Advanced breast cancer
[12]
      • 

    • Non-small cell lung cancer (NSCLC)
[13]
      • 

    • Multiple myeloma
[14]
      • 

    • Advanced melanoma
[15]
    • 

  • Phase III

    • A comparison of dinaciclib and ofatumumab for treatment of CLL
[16]


References





    

  1. 
^ Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. (August 2010). 
"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor". Molecular Cancer Therapeutics. 9 (8): 2344–2353. 
doi:
10.1158/1535-7163.MCT-10-0324. 
PMID 
20663931.

    2. 

  2. 
^ Bose P, Simmons GL, Grant S (June 2013). 
"Cyclin-dependent kinase inhibitor therapy for hematologic malignancies". Expert Opinion on Investigational Drugs. 22 (6): 723–738. 
doi:
10.1517/13543784.2013.789859. 
PMC 
4039040. 
PMID 
23647051.

    3. 

  3. 
^ 
"Dinaciclib". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 January 2017.

    4. 

  4. 
^ Martin MP, Olesen SH, Georg GI, Schönbrunn E (November 2013). 
"Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains". ACS Chemical Biology. 8 (11): 2360–2365. 
doi:
10.1021/cb4003283. 
PMC 
3846258. 
PMID 
24007471.

    5. 

  5. 
^ Nguyen TK, Grant S (March 2014). 
"Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism". Molecular Cancer Therapeutics. 13 (3): 662–674. 
doi:
10.1158/1535-7163.MCT-13-0714. 
PMC 
3970263. 
PMID 
24362465.

    6. 

  6. 
^ Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, et al. (2013). 
"The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling". PLOS ONE. 8 (3): e59588. 
Bibcode:
2013PLoSO...859588D. 
doi:
10.1371/journal.pone.0059588. 
PMC 
3601112. 
PMID 
23527225.

    7. 

  7. 
^ Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, et al. (December 2012). 
"The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells". Leukemia. 26 (12): 2554–2557. 
doi:
10.1038/leu.2012.144. 
PMC 
3645353. 
PMID 
22791353.

    8. 

  8. 
^ Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, et al. (October 2011). 
"Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models". Cancer Biology & Therapy. 12 (7): 598–609. 
doi:
10.4161/cbt.12.7.16475. 
PMC 
3218385. 
PMID 
21768779.

    9. 

  9. 
^ Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J, et al. (June 2011). 
"The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells". Molecular Cancer Therapeutics. 10 (6): 1018–1027. 
doi:
10.1158/1535-7163.MCT-11-0167. 
PMC 
4727401. 
PMID 
21490307.

    10. 

  10. 
^ Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ (March 2013). 
"Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor". Cell Death & Disease. 4 (3): e566. 
doi:
10.1038/cddis.2013.101. 
PMC 
3613821. 
PMID 
23538447.

    11. 

  11. 
^ Ambrozkiewicz MC, Bessa P, Salazar-Lázaro A, Salina V, Tarabykin V (November 2017). "Satb2Cre/+ mouse as a tool to investigate cell fate determination in the developing neocortex". Journal of Neuroscience Methods. 291: 113–121. 
doi:
10.1016/j.jneumeth.2017.07.023. 
PMID 
28782628. 
S2CID 
140208929.

    12. 

  12. 
^ Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, et al. (June 2014). "Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer". Clinical Breast Cancer. 14 (3): 169–176. 
doi:
10.1016/j.clbc.2013.10.016. 
PMID 
24393852.

    13. 

  13. 
^ Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, et al. (February 2014). "Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer". Lung Cancer. 83 (2): 219–223. 
doi:
10.1016/j.lungcan.2013.11.020. 
PMID 
24388167.

    14. 

  14. 
^ Clinical trial number 
NCT01096342 for "Phase II Trial of CDK Inhibitor Sch 727965 in Multiple Myeloma" at 
ClinicalTrials.gov

    15. 

  15. 
^ Clinical trial number 
Phase II Trial of Sch 727965 (NSC 747135) in Patients with Stage IV Melanoma NCT00937937A Phase II Trial of Sch 727965 (NSC 747135) in Patients with Stage IV Melanoma  at 
ClinicalTrials.gov

    16. 

  16. 
^ Clinical trial number 
NCT01580228 for "A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia" at 
ClinicalTrials.gov

    17. 



External links












Retrieved from "
https://en.wikipedia.org/?title=Dinaciclib&oldid=1188855566"

					
				

			
			
		

		










Videos


Youtube | 
Vimeo | 
Bing


Websites


Google | 
Yahoo | 
Bing


Encyclopedia


Google | 
Yahoo | 
Bing


Facebook














                        

                            

                            Top Of Page
                            


                            Home • 
                            Search • 
                            Translate
                            


                            ©  
                                CSE